ICH E22 General considerations for patient preference studies - Scientific guideline
Submitted by Anonymous (not verified) on 24 June 2026 - 12:18
ICH E22 General considerations for patient preference studies - Scientific guideline
Appendix 1: Acceptable intakes established for N-nitrosamines
Submitted by Anonymous (not verified) on 24 June 2026 - 12:01
Appendix 1: Acceptable intakes established for N-nitrosamines
Fee regulation working arrangements
Submitted by Anonymous (not verified) on 24 June 2026 - 10:00
Fee regulation working arrangements
Cookies
Submitted by Anonymous (not verified) on 24 June 2026 - 9:00
Cookies
Human medicines European public assessment report (EPAR): Hemangiol, propranolol, Date of authorisation: 23/04/2014, Revision: 8, Status: Authorised
Submitted by Anonymous (not verified) on 23 June 2026 - 16:40
Human medicines European public assessment report (EPAR): Hemangiol, propranolol, Date of authorisation: 23/04/2014, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 23 June 2026 - 16:34
Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 75, Status: Authorised
Submitted by Anonymous (not verified) on 23 June 2026 - 16:30
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 75, Status: Authorised
Human medicines European public assessment report (EPAR): Balversa, erdafitinib, Date of authorisation: 22/08/2024, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 23 June 2026 - 16:28
Human medicines European public assessment report (EPAR): Balversa, erdafitinib, Date of authorisation: 22/08/2024, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Lynkuet, elinzanetant, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 23 June 2026 - 16:25
Human medicines European public assessment report (EPAR): Lynkuet, elinzanetant, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
EMEA-000925-PIP02-10
Submitted by Anonymous (not verified) on 23 June 2026 - 16:22
EMEA-000925-PIP02-10